The Dow Jones Industrial Average (DJI) is up 81 points this afternoon, while the S&P 500 Index (SPX) and Nasdaq Composite (IXIC) are lower, with stocks kicking off a new month after a February decline. Rising bond yields are again weighing on sentiment, as traders unpack the ISM manufacturing index, which came in at 47.7% for last month -- still in contraction territory
Options traders are targeting Marqeta Inc (Nasdaq: MQ) today, with 87,000 calls and 36,000 puts across the tape so far, or 95 times the typical intraday volume. The March 5 call is the most popular, with new positions opening there. The company reported better-than-expected fourth-quarter results, but J.P. Morgan Securities downgraded the equity to "neutral" from "underweight," citing a muted 2023 growth outlook. No fewer than four other analysts cut their price targets as well. MQ is down 20.6% at $4.61 at last check, and earlier hit a fresh record low of $4.27.
Reata Pharmaceuticals Inc (Nasdaq: RETA) stock is up a whopping 169.5% to trade at $84.02 at last glance, and earlier hit a one-year high of $90, after the U.S. Food and Drug Administration (FDA) approved the company's Skyclarys treatment for Friedreich's ataxia, a rare genetic disorder. No fewer than eight analysts lifted their price targets after the news. Year-over-year, RETA is up 153.7%.
The shares of Xometry Inc (Nasdaq: XMTR) are down 41.3% at $17.84 at last check, and dipped to at record low of $17.02 after the software company's wider-than-expected fourth-quarter losses and revenue miss. Year-to-date, the equity is down 45.8%.
More By This Author:
Wall Street Posts February Losses On Shaky Fed Policy
Monthly Losses In Sight For Major Indexes
Wall Street Logs Modest Wins As Bond Yields Cool
Comments
Log in or sign up to join the conversation.